Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO7444973
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RO7444973 is a bispecific T-cell engaging antibody developed by Roche (Hoffmann-La Roche) that targets both the tumor-associated antigen human leukocyte antigen (HLA)-A2-restricted, melanoma-associated antigen A4 (MAGE-A4), and the T-cell surface antigen CD3. Its mechanism of action involves redirecting T cells to recognize and kill MAGE-A4-positive tumor cells in patients carrying the HLA-A*02:01 allele. The drug was investigated for use in unresectable and/or metastatic solid tumors expressing MAGE-A4, but its clinical development was terminated after a phase 1 trial[1][2][6].
- Other names
- Anti-HLA-A2-MAGE-A4/Anti-CD3 Bispecific Antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)MAGE-A4 peptide-HLA-A*02:01 complexMAGEA4 (Melanoma-associated antigen A4)
Beyond the preview
Go deeper on RO7444973.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO7444973.